Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Acarbose, an α-glucosidase inhibitor, has been shown to have antineoplastic effects on colorectal cancer in biomarker studies. We assessed the association between acarbose use in patients with diabetes and incident colorectal cancer. RESEARCH DESIGN AND METHODS: We conducted a nationwide, population-based study using a large cohort with diabetes in the Taiwan National Health Insurance Research Database. Patients with newly diagnosed diabetes (n = 1,343,484) were enrolled between 1998 and 2010. One control subject not using acarbose was randomly selected for each subject using acarbose after matching for age, sex, diabetes onset, and comorbidities. Cox proportional hazards regression with a competing risks analysis was used to calculate the hazard ratios (HRs) and 95% CIs for the association between acarbose use and incident colorectal cancer for each eligible case-control pair (n = 199,296). RESULTS: There were 1,332 incident cases of colorectal cancer in the cohort with diabetes during the follow-up period of 1,487,136 person-years. The overall incidence rate was 89.6 cases per 100,000 person-years. Patients treated with acarbose had a 27% reduction in the risk of colorectal cancer compared with control subjects. The adjusted HRs were 0.73 (95% CI 0.63–0.83), 0.69 (0.59–0.82), and 0.46 (0.37–0.58) for patients using >0 to <90, 90 to 364, and ≥365 cumulative defined daily doses of acarbose, respectively, compared with subjects who did not use acarbose (P for trend < 0.001). CONCLUSIONS: Acarbose use reduced the risk of incident colorectal cancer in patients with diabetes in a dose-dependent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607 · cited 1×
“low-dose aspirin have a risk reduction in the colorectal cancer incidence (10– 13), whereas insulin and sulfonylureas have been shown to promote cancer development (14,15).”
BackgroundDiabetes and colorectal cancer incidence in the cohort of Swedish men
Larsson, S. C., Giovannucci, E., & Wolk, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1805 · Cited by 101
Wolever, T., Chiasson, J.-L., Josse, R., Hunt, J., Palmason, C., Rodger, N., Ross, S., Ryan, E., & Tan, M. (1997) · International Journal of Obesity · doi:10.1038/sj.ijo.0800468 · Cited by 71
Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes
Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group (2013) · Diabetes Care · doi:10.2337/dc11-2197 · Cited by 37
Self-citation
Cited by
Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes: Assessment of Causal Relations
Livesey, G., Taylor, R., Livesey, H. F., Buyken, A. E., Jenkins, D. J. A., Augustin, L. S. A., Sievenpiper, J. L., Barclay, A. W., Liu, S., Wolever, T. M. S., et al. (2019) · Nutrients · doi:10.3390/nu11061436 · Cited by 163
“Recent evidence on achieving lower GI or GL diets using an inhibitor of carbohydrate digestion, acarbose, is also consistent with higher GI or GL promoting colorectal cancer [137].”
Chang, H.-Y., Singh, S., Mansour, O., Baksh, S., & Alexander, G. C. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.3034 · Cited by 163
Lysosomal glucose sensing and glycophagy in metabolism
Mancini, M. C., Noland, R. C., Collier, J. J., Burke, S. J., Stadler, K., & Heden, T. D. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.07.008 · Cited by 26
Metadata
- Authors
- Tseng, Y.-H., Tsan, Y.-T., Chan, W.-C., Sheu, W. H.-H., & Chen, P.-C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-25
- Volume
- 38
- Issue
- 11
- Pages
- 2068-2074
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2109952655
- Cited by
- 67
- References
- 4
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.